Clinical utility of telomeres as diagnostic and short-term prognostic markers in loco-regional treatment of hepatocellular carcinoma

Table 5 Laboratory findings before and after treatment in the hepatocellular carcinoma group

Variables		Before	After	Change	P value
INR	mean ± SD	1.2 ± 0.2	1.3 ± 0.2	0.1 ± 0.2	0.0211,3
	Range	1.0-1.7	1.0-1.6	-0.3 to 0.5
Total bilirubin (mg/dL)	mean ± SD	1.0 ± 0.5	1.2 ± 0.5	0.2 ± 0.5	0.0841
	Range	0.2-2.1	0.4-2.2	-1.3 to 1.1
Albumin (g/dL)	mean ± SD	3.8 ± 0.6	3.4 ± 0.4	-0.4 ± 0.4	< 0.0011,3
	Range	2.8-4.8	2.7-4.3	-1.2 to 0.3
ALT (U/L)	mean ± SD	28.1 ± 15.4	24.1 ± 15.3	-4.0 ± 16.9	0.2011
	Range	6.0-76.0	9.0-70.0	-62.0 to 43.0
AST (U/L)	mean ± SD	43.8 ± 26.5	38.2 ± 16.8	-5.6 ± 21.9	0.1721
	Range	10.0-140.0	21.0-110.0	-86.0 to 21.0
AFP (ng/mL)	Median (1st-3rd IQ)	31.5 (6.2-235.0)	11.5 (4.2-101.0)	-14.9 (-192.0 to -1.9)	< 0.0012,3
	Range	0.9-800.0	0.8-388.0	-456.0 to 2.9
Telomere length (× 103)	Median (1st-3rd IQ)	1.3 (1.0-1.8)	1.6 (1.0-1.9)	0.3 (-0.8 to 0.8)	0.5042
	Range	0.5-3.5	0.6-5.3	-1.8 to 4.3

¹Paired t-test.

²Wilcoxon signed-rank test.

³Significant.

Total = 30. INR: International normalized ratio; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alpha fetoprotein; IQ: Interquartile.